#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lip and/or oral cavity cancer Lennox-Gastaut syndrome Interstitial lung disease Haemophilia B with anti factor IX Osteomyelitis Immunoglobulin G4 related disease Nasopharyngeal cancer Synovial sarcoma recurrent Systemic sclerosis pulmonary Adrenocortical carcinoma Glycogen storage disease type II Eosinophilic oesophagitis Gaucher's disease type I Anaplastic large cell lymphoma T- and null-cell types Antithrombin III deficiency More trials…

    Learn about Rare Diseases

    Epidermolysis bullosa – Trials in Disease Mantle cell lymphoma stage III – Basic Information Usher’s syndrome – Trials in Disease Toxic epidermal necrolysis Mantle cell lymphoma stage II – Trials in Disease Systemic sclerosis pulmonary – Life with Disease Netherton’s syndrome – Life with Disease Ornithine transcarbamoylase deficiency – Basic Information Hepatic angiosarcoma Pleural mesothelioma malignant – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Montelukast Sodium Atuliflapon TROFOLASTAT Protrans Ebastine ABBV-8736 ADMILPARANT Sulfonamides, Urea Derivatives Tobevibart Transcon Il-2Β/Γ EGANELISIB LY4170156 7-Ethyl-10-Hydroxycamptothecin Neratinib Aldesleukin Salmeterol Xinafoate Hct116-A Oxybuprocaine Hydrochloride Trientine Dihydrochloride Crisantaspase More therapies…

    Learn about Your Condition

    Liposarcoma Endometrial stromal sarcoma Altered state of consciousness Vascular calcification Bronchopulmonary aspergillosis Diabetic foot Neurofibrosarcoma Angelman's syndrome Laparotomy Cardiac sarcoidosis Thymoma Rhabdomyosarcoma recurrent Testis cancer Pharyngeal cancer stage I Triple negative breast cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Type 2 diabetes mellitus

  • Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

    Recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Semaglutide
    Germany Hungary Poland Romania Slovakia Spain

  • A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

    Recruiting

    3 1
    Investigated Drugs:
    • Azd5004
    Bulgaria Czechia Germany Poland

  • A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Czechia Denmark Germany Greece Hungary Poland +1

  • Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Bulgaria Denmark Germany Spain

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Investigated Drugs:
    • Semaglutide
    Bulgaria Croatia Germany Hungary Poland Portugal +1

  • A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Croatia Hungary Italy Romania Slovakia
1 2 3 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!